NCT02534207View on ClinicalTrials.gov

Basmisanil Positron Emission Tomography Study in Japanese Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

November 30, 2015

Conditions
Healthy Volunteer
Interventions
DRUG

Basmisanil

Single oral dose: Basmisanil doses between 20 milligrams (mg) and 960 mg may be used in this study. The planned doses for the first two participants are 160 mg and 480 mg, respectively. Basmisanil dose for subsequent participants will be decided by the investigator and sponsor during the study, based on on-going review of emerging data.

Trial Locations (4)

NW10 7EW

Hammersmith Medicines Research; Central Middlesex Hospital, London

London

W12 0NN

Imanova Limited, London

London

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02534207 - Basmisanil Positron Emission Tomography Study in Japanese Volunteers | Biotech Hunter | Biotech Hunter